Venous thromboembolic disease: Clinical Practice Guidelines in Oncology

Michael B. Streiff; Paula L. Bockenstedt; Spero R. Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Annemarie E. Fogerty; Shuwei Gao; Samuel Z. Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Nicole Kuderer; Jason T. Lee; Michael M. Millenson; Anne T. Neff; Thomas L. Ortel; Tanya Siddiqi; Judy L. Smith; Gary C. Yee; Anaadriana Zakarija; Nicole McMillian; Maoko Naganuma

doi:10.6004/jnccn.2013.0163

Venous thromboembolic disease: Clinical Practice Guidelines in Oncology

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. YeeAnaadriana Zakarija, Nicole McMillian, Maoko Naganuma

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Abstract

Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.

Original language	English (US)
Pages (from-to)	1402-1429
Number of pages	28
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	11
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2013.0163
State	Published - Nov 1 2013

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2013.0163

Cite this

Streiff, M. B., Bockenstedt, P. L., Cataland, S. R., Chesney, C., Eby, C., Fanikos, J., Fogerty, A. E., Gao, S., Goldhaber, S. Z., Hassoun, H., Hendrie, P., Holmstrom, B., Kuderer, N., Lee, J. T., Millenson, M. M., Neff, A. T., Ortel, T. L., Siddiqi, T., Smith, J. L., ... Naganuma, M. (2013). Venous thromboembolic disease: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network, 11(11), 1402-1429. https://doi.org/10.6004/jnccn.2013.0163

Streiff, MB, Bockenstedt, PL, Cataland, SR, Chesney, C, Eby, C, Fanikos, J, Fogerty, AE, Gao, S, Goldhaber, SZ, Hassoun, H, Hendrie, P, Holmstrom, B, Kuderer, N, Lee, JT, Millenson, MM, Neff, AT, Ortel, TL, Siddiqi, T, Smith, JL, Yee, GC, Zakarija, A, McMillian, N & Naganuma, M 2013, 'Venous thromboembolic disease: Clinical Practice Guidelines in Oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 11, pp. 1402-1429. https://doi.org/10.6004/jnccn.2013.0163

@article{8ee572422a0c4351af72ae5d95f6a147,

title = "Venous thromboembolic disease: Clinical Practice Guidelines in Oncology",

abstract = "Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.",

author = "Streiff, {Michael B.} and Bockenstedt, {Paula L.} and Cataland, {Spero R.} and Carolyn Chesney and Charles Eby and John Fanikos and Fogerty, {Annemarie E.} and Shuwei Gao and Goldhaber, {Samuel Z.} and Hani Hassoun and Paul Hendrie and Bjorn Holmstrom and Nicole Kuderer and Lee, {Jason T.} and Millenson, {Michael M.} and Neff, {Anne T.} and Ortel, {Thomas L.} and Tanya Siddiqi and Smith, {Judy L.} and Yee, {Gary C.} and Anaadriana Zakarija and Nicole McMillian and Maoko Naganuma",

year = "2013",

month = nov,

day = "1",

doi = "10.6004/jnccn.2013.0163",

language = "English (US)",

volume = "11",

pages = "1402--1429",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "11",

}

TY - JOUR

T1 - Venous thromboembolic disease

T2 - Clinical Practice Guidelines in Oncology

AU - Streiff, Michael B.

AU - Bockenstedt, Paula L.

AU - Cataland, Spero R.

AU - Chesney, Carolyn

AU - Eby, Charles

AU - Fanikos, John

AU - Fogerty, Annemarie E.

AU - Gao, Shuwei

AU - Goldhaber, Samuel Z.

AU - Hassoun, Hani

AU - Hendrie, Paul

AU - Holmstrom, Bjorn

AU - Kuderer, Nicole

AU - Lee, Jason T.

AU - Millenson, Michael M.

AU - Neff, Anne T.

AU - Ortel, Thomas L.

AU - Siddiqi, Tanya

AU - Smith, Judy L.

AU - Yee, Gary C.

AU - Zakarija, Anaadriana

AU - McMillian, Nicole

AU - Naganuma, Maoko

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.

AB - Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=84891938450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891938450&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0163

DO - 10.6004/jnccn.2013.0163

M3 - Article

C2 - 24225973

AN - SCOPUS:84891938450

SN - 1540-1405

VL - 11

SP - 1402

EP - 1429

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

Venous thromboembolic disease: Clinical Practice Guidelines in Oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this